Chapter 56: Fluid and Electrolyte Disturbances – Comprehensive Study Notes (Sodium, Water, Hyponatremia, Hypernatremia, and Potassium Disorders)

Fluid Compartments, Osmolality, and Water Balance

  • Water is the most abundant body constituent: ~50% body weight in women, ~60% in men.
  • Total-body water (TBW) distribution:
    • Intracellular fluid (ICF): 55–75%
    • Extracellular fluid (ECF): 25–45%
  • ECF subdivided into intravascular (plasma water) and extravascular (interstitial) spaces in a ratio of 1:3.
  • Fluid movement between intravascular and interstitial spaces occurs across capillary walls governed by Starling forces:
    • Capillary hydraulic pressure vs oncotic pressure
    • Transcapillary gradient favors plasma ultrafiltrate moving into the interstitial space
    • Return to intravascular via lymphatics
  • Osmolality: solute concentration expressed as mOsm/kg; water diffuses to equilibrate osmolality (ECF osmolality ≈ ICF osmolality).
  • Major extracellular solutes: Na+ with Cl− and HCO3−; major intracellular osmoles: K+ and organic phosphate esters (ATP, creatine phosphate, phospholipids).
  • Tonicity (effective osmolality) is determined by solutes that cause water shifts; ineffective osmoles (e.g., urea) do not drive water movement.
  • Solute distribution differences arise from transporters, channels, and ATP-driven pumps.
  • Water balance is maintained by vasopressin (AVP), water intake, and renal water handling to keep osmolality between ~280 and 295 mOsm/kg.
  • Key concept: the absolute plasma Na+ concentration alone does not reveal volume status; volume status modulates AVP response and water handling.

Vasopressin (AVP) and the Osmotic Set Point

  • AVP synthesis: magnocellular neurons in the hypothalamus; released from the posterior pituitary (neurohypophysis).
  • Osmoreceptors sense circulating osmolality via stretch-activated cation channels; respond to small changes.
  • Threshold for AVP release and thirst around ~285 mOsm/kg; above threshold, AVP release and thirst increase linearly with osmolality.
    • Fig. 56-1 (described): euvolemic individuals show detectable AVP ~285 mOsm/kg; osmotic threshold is lower in hypovolemia (steeper response) and higher in hypervolemia (reduced sensitivity).
  • AVP half-life is short (~10–20 min); changes in ECF volume or osmolality quickly affect water homeostasis.
  • Nonosmotic activators of AVP release/thirst: nausea, intracerebral angiotensin II, serotonin, and various drugs.
  • AVP actions on kidney:
    • V2 receptors in collecting ducts and thick ascending limb (TALH) activate cAMP and PKA-dependent phosphorylation of transport proteins, enhancing Na+–Cl− and K+ transport in TALH and water reabsorption in collecting duct (CD).
    • This promotes the countercurrent multiplication/concentrating mechanism that increases medullary interstitial osmolality and drives water reabsorption across CD:
    • Descending limb water permeability via AQP1 (descending thin limb) and aquaporin-1 channels.
    • Thin ascending limb Na+–K+–2Cl− reabsorption via NKCC2; paracellular Na+ transport; Cl− handling via CLC-K1.
    • Urea transport supports medullary gradient and water excretion control.
  • AVP–cAMP–PKA pathway (Figure 56-3): AVP binds V2R, AC activity↑, cAMP↑, PKA↑; cytoplasmic vesicles carrying aquaporin-2 (AQP2) insert into luminal membrane to increase CD water permeability; after AVP wanes, AQP2 is internalized.
  • AQP2, AQP3, AQP4 form the transcellular water reabsorption pathway in the CD.
  • Final common pathway: antidiuresis via AVP-dependent AQP2 insertion yields concentrated urine (osmolality up to ~1200 mOsm/kg); absence of AVP yields hypotonic urine (osmolality ~30–50 mOsm/kg).
  • Abnormalities in this pathway underlie many water balance disorders (e.g., diabetes insipidus).

Renal Concentrating Mechanism (Overview)

  • The renal concentrating mechanism requires coordinated transport across proximal and distal nephron segments, and the medullary gradient (inner medulla).
  • Key components (from TALH to CD):
    • TALH: AVP-induced, PKA-dependent phosphorylation increases activity of NKCC2 Na+–K+–2Cl− cotransporter and related transporters; enhances interstitial osmolality.
    • Descending limb (DTLH): water reabsorption via AQP1; water follows the osmotic gradient.
    • Thin ascending limb (TAL) and thin ascending limb Na+ transport: passive Na+–Cl− reabsorption via paracellular routes (with CLC-K1 channel involvement and pendrin in intercalated cells).
    • Proximal and distal nephron contributions: proximal reabsorption and distal nephron fine-tuning contribute to the concentrating mechanism.
    • Renal urea handling: UT transporters contribute to medullary gradient formation and free water excretion capacity.
  • Figure 56-2: Diagram of transport proteins (AQP, NKCC2, ROMK, CLC-K1, pendrin, UT); loop of Henle, collecting duct depicted.
  • Final concentrating step in CD: AVP → AQP2 insertion in principal cells; AQP3/4 basolateral channels complete transcellular reabsorption; osmolality equilibrates across CD epithelium to yield concentrated urine when AVP present.
  • Under antidiuretic conditions: urine osmolality can reach very high values; without AVP: dilute urine predominates.

Sodium and Water Disorders: Core Concepts

  • Water intake and circulating AVP maintain serum osmolality; volume status modulates AVP release sensitivity (threshold shifts with hypovolemia/hypervolemia).
  • Absolute plasma Na+ does not directly indicate volume status; volume assessment is essential for diagnosis and therapy.
  • AVP also contributes to circulatory integrity by vasoconstriction (V1A) and by promoting Na+–water retention; in the kidney AVP increases water reabsorption via V2R.
  • The final common pathway (AQP2 insertion) is central to most water homeostasis disorders (e.g., diabetes insipidus when AQP2 insertion is reduced/absent).

Hyponatremia (Serum Na+ < 135 mM)

  • Hyponatremia is common in hospitalized patients (up to ~22%). Often due to AVP excess and/or increased renal sensitivity to AVP with free water intake.
  • Diagnostic framework depends on extracellular fluid volume (ECFV): hypovolemic, euvolemic, hypervolemic hyponatremia (Fig. 56-5).
  • SIAD (syndrome of inappropriate antidiuresis) is a major euvolemic cause; many etiologies exist (malignancy, pulmonary disease, CNS disorders, drugs).
  • Low solute intake (beer potomania) can cause hyponatremia with very low solute intake and dilute urine; urine osmolality may be low (<100 mOsm/kg) and urine Na+ very low (<10–20 mM).
  • Acute hyponatremia (symptomatic) is a medical emergency; chronic hyponatremia requires careful correction to avoid osmotic demyelination syndrome (ODS).

Diagnostic Approach to Hyponatremia

  • First assess clinical status and volume status (hypovolemic/euvolemic/hypervolemic): history, exam, and risk factors.
  • Laboratory evaluation includes:
    • Serum osmolality and effective osmolality (tonicity): $\text{tonicity} \,=\, \text{osmolality} - (\text{uric acid}/2.8)$ (if using mg/dL units).
    • Serum uric acid: SIAD typically hypouricemic (<4 mg/dL); volume depletion hyperuricemic.
    • Serum glucose: hyperglycemia lowers measured Na+ by ~$1.6$–$2.4$ mM per 100 mg/dL glucose; true hyponatremia corrects with glucose correction.
    • Thyroid, adrenal, and pituitary function (cosyntropin test for primary adrenal insufficiency).
  • Urine studies are crucial:
    • Urine Na+:
    • Urine osmolality: >400 mOsm/kg supports AVP-driven water retention; <100 mOsm/kg suggests primary polydipsia.
    • Urine K+ and calculation of urine-to-plasma electrolyte ratio ([Na+] + [K+])/ [Na+] to guide fluid restriction needs.
    • Urine osmolality and Na+ can overlap in SIAD vs hypovolemia, especially in elderly; the gold standard is response to isotonic saline (plasma Na+ correction after volume repletion).
  • Special scenarios:
    • Thiazide-associated hyponatremia may mimic SIAD but typically resolves after stopping thiazides.
    • Beer potomania has low urine osmolality and very low urine Na+.

Classification of Hyponatremia by Volume Status

  • Hypovolemic hyponatremia:
    • Intravascular volume depletion with nonrenal Na+ loss (GI losses, renal losses from diuretics, mineralocorticoid deficiency).
    • Urine Na+ typically >20 mM if renal salt loss; <20 mM if nonrenal losses (in absence of hypervolemic states).
  • Euvolemic hyponatremia:
    • SIAD is the classic cause; hypothyroidism and secondary adrenal insufficiency can cause euvolemic hyponatremia.
    • SIAD patterns: various AVP secretion patterns (unregulated AVP, non-suppressible at low osmolality, reset osmostat, or AVP-independent cause such as nephrogenic SIAD).
  • Hypervolemic hyponatremia:
    • Conditions with edema and low effective arterial volume (CHF, cirrhosis, nephrotic syndrome).
    • Urine Na+ typically very low (<10 mM) after adequate hydration; hyponatremia reflects total body Na+ retention with excess water.

Low Solute Intake Hyponatremia

  • Beer potomania and similar diets with very low solute intake can cause hyponatremia with low urine osmolality and low urine Na+.
  • Management includes resumption of normal solute intake and saline hydration; AVP levels are suppressed with salt/salt-containing fluids.

Clinical Features and Complications

  • Hyponatremia causes generalized cellular swelling; neurologic symptoms predominate (nausea, headache, confusion, seizures, coma).
  • Acute hyponatremia can cause brain edema and potentially fatal herniation; risk higher in women before menopause for encephalopathy.
  • Acute hyponatremia from iatrogenic hypotonic fluids or MDMA (Ecstasy) often involves nonosmotic AVP rise and high water intake.
  • Chronic hyponatremia can cause gait disturbances, cognitive impairment, and increased fracture risk due to bone density loss; osmotic demyelination risk with overly rapid correction.

Treatment Principles for Hyponatremia

  • Goals:
    1) Correct symptoms and avoid cerebral edema; 2) Avoid osmotic demyelination syndrome (ODS) by limiting rate of Na+ correction.
    3) Address underlying cause.
  • General approach depends on etiology and rate of onset.
  • Euvolemic hyponatremia (e.g., SIAD): treat underlying cause; if refractory, consider AVP antagonists (vaptans) or salt + loop diuretic strategies; fluid restriction is common first-line.
  • Hypovolemic hyponatremia: isotonic saline IV typically corrects AVP-driven water retention; rate of correction may need to be slowed if hyponatremia is chronic (>48 h).
  • Hypervolemic hyponatremia (CHF, cirrhosis): treat underlying edema/illness; hypertonic saline is not standard; vasopressor antagonists and diuretic strategies may be used with caution.
  • Beer potomania/low solute hyponatremia: saline hydration and dietary solute repletion.
  • Acute symptomatic hyponatremia: hypertonic saline (3% NaCl, ~513 mM) to raise Na+ by ~1–2 mM/h, total 4–6 mM, with close monitoring every 2–4 hours; bolus 100 mL 3% NaCl can be more effective than infusion.
  • Correction rates to avoid ODS:
    • In chronic hyponatremia: aim for <8–10 mM increase in 24 h and <18 mM in 48 h.
    • If overcorrection occurs, reinduce or stabilize with desmopressin (DDAVP) and/or free water (D5W).
  • Adjunctive therapies for SIAD or persistent hyponatremia:
    • Water restriction; in SIAD, consider AVP antagonists (tolvaptan, conivaptan), urea, salt tablets with loop diuretics, or combination strategies.
    • Demeclocycline as a second-line agent (risk of nephrotoxicity).
    • Oral urea as an osmotically active solute to enhance free water excretion.
    • In persistent SIAD, tolvaptan (oral V2 antagonist) approved for adults; monitor for liver toxicity; restricted use (
      <1–2 months).

Hypernatremia (Serum Na+ > 145 mM)

  • Etiology: usually a water deficit with or without electrolyte loss; less commonly Na+ gain.
  • Causes of water loss: insensible losses (fever, heat, fever, ventilation), diarrhea, osmotic diuresis (hyperglycemia, urea, postobstructive diuresis, mannitol).
  • Causes of water diuresis: central DI or nephrogenic DI (NDI), often with polyuria and low urine osmolality; pregnancy (gestational DI) due to placental vasopressinases; lithium-related NDI; hypercalcemia; hypokalemia can also contribute to NDI.
  • Diagnostic approach:
    • Check serum and urine osmolality; if urine osmolality is <500 mOsm/kg with ongoing water loss, assess for DI and solute diuresis.
    • If hypernatremia with high AVP: DI (central or nephrogenic); measure copeptin as adjunct; DDAVP challenge helps distinguish central DI (urine osmolality rises with DDAVP) from nephrogenic DI (no rise).
    • In pregnancy, use protease inhibitors to prevent vasopressinase degradation of AVP.
  • Treatment:
    • Correct underlying cause; replace free water deficit slowly, typically over 48–72 h, aiming to increase Na+ by no more than ~10 mM per day.
    • Free water replacement can be oral or IV (D5W); avoid rapid correction to prevent cerebral edema.
    • In DI, DDAVP can restore water retention (central DI); in NDI, management includes thiazides, amiloride (to limit lithium entry in lithium-induced NDI), NSAIDs (for chronic NDI, with toxicity risks).
    • If hypernatremia is due to renal water loss, calculate urinary electrolyte-free water clearance to gauge ongoing losses and daily replacement needs.
  • Special considerations:
    • In central DI during pregnancy, DDAVP is resistant to placental vasopressinase and is effective.
    • Rapid correction in children can predispose to cerebral edema; monitor closely.

Potassium Homeostasis and Disorders

  • Potassium (K+) homeostasis ensures plasma K+ stays 3.5–5.0 mM; most total body K+ is intracellular (≈98%), especially in muscle.
  • Kidneys play a dominant role in K+ balance; renal handling along the nephron determines net excretion.
  • Distal nephron handling:
    • Principal cells: ENaC-mediated Na+ entry creates a lumen-negative potential driving K+ secretion via ROMK and BK channels.
    • Aldosterone increases ENaC activity, amplifying K+ secretion; distal Na+ delivery modulates K+ excretion.
  • Key channels:
    • ROMK (Kir1.1) drives constitutive K+ secretion.
    • BK (big potassium) channels mediate flow-dependent K+ secretion.
    • Alpha-intercalated cells reabsorb K+ via H+-K+-ATPase in low-K+ states.
  • Important concept: distal Na+ delivery and flow rate strongly influence K+ secretion; diuretics that increase distal Na+ delivery promote hypokalemia; conversely, reduced distal Na+ delivery can cause hyperkalemia.
  • Aldosterone has a major influence on K+ excretion; conditions with aldosterone excess promote hypokalemia, while hypoaldosteronism can cause hyperkalemia.
  • Potassium disorders arise from multiple mechanisms, including redistribution, loss, and poor excretion, and are frequently affected by magnesium status and acid-base balance.

Hypokalemia (K+ < 3.5 mM)

  • Prevalence: up to 20% of hospitalized patients; associated with higher mortality.
  • Mechanisms: redistribution into cells or loss (renal or nonrenal); hypomagnesemia can cause refractory hypokalemia.
  • Major causes (highlights from Table 56-4):
    • Decreased intake (starvation, clay ingestion).
    • Redistribution into cells (alkalosis, insulin, beta-2 adrenergic activity, thyrotoxic periodic paralysis, etc.).
    • Increased loss: nonrenal (GI losses, sweating) and renal (diuretics, mineralocorticoid excess [primary or secondary hyperaldosteronism], Liddle’s syndrome, apparent mineralocorticoid excess [11β-HSD2 deficiency or glycyrrhetinic acid], vomiting with bicarbonaturia, renal tubular acidoses, certain drugs and toxins).
    • Bartter syndrome (BS) and Gitelman syndrome (GS) cause chronic hypokalemia via renal losses; GS is due to NKCC2-like effects in DCT? (GS is NCC loss of function in DCT).
  • Clinical features: muscle weakness, cramps; hypokalemic periodic paralysis in select conditions; arrhythmias with QT prolongation; weakness in skeletal muscles; rhabdomyolysis risk; nephrocalcinosis in BS; chondrocalcinosis in GS.
  • Diagnostic approach:
    • History of medications (diuretics, laxatives), diet (licorice), symptoms (paralysis, diarrhea).
    • Physical examination: BP, volume status; check for signs of specific disorders (hyperthyroidism, Cushing’s).
    • Initial labs: electrolytes, BUN, creatinine, osmolality, magnesium, calcium, CBC; urinary pH/osmolarity/creatinine/electrolytes; 24-h urinary K+ excretion (
    • Urinary chloride helps distinguish causes (low Cl− with vomiting; high Cl− with GS or diuretic use).
    • Urine Na+, urine K+, and Cl− patterns help differentiate chronic hypokalemia etiologies (e.g., vomiting vs GS vs diuretic abuse).
    • Genetic testing for suspected familial syndromes (Liddle’s, FH-I/GRA, SAME, Bartter, Gitelman).
  • Treatment:
    • Correct underlying cause and replace K+ gradually (oral KCl preferred; IV KCl only when necessary, e.g., severe symptoms or inability to take oral).
    • IV KCl dosing: typically 20–40 mmol per liter IV fluids; avoid high concentrations; IV rate often limited to 10–20 mmol/h in critical cases; monitor potassium closely.
    • Magnesium repletion if hypomagnesemic (refractory hypokalemia).
    • Consider strategies to reduce renal K+ loss (e.g., minimize non-K+-sparing diuretics, appropriate combinations of diuretics).

Hyperkalemia (K+ > 5.5 mM; severe > 6.0 mM)

  • Causes: redistribution, increased intake, and particularly reduced excretion (CKD, hypoaldosteronism, drugs that inhibit renin–angiotensin–aldosterone axis, ENaC inhibitors, NSAIDs, cyclooxygenase inhibitors, cyclosporine/tacrolimus, etc.).
  • Pseudohyperkalemia: spurious elevations due to hemolysis, thrombocytosis, leukocytosis, venipuncture issues; cooling of blood or processing can alter readings.
  • Key mechanisms/causes summarized (Table 56-5):
    • Pseudohyperkalemia; intravascular shifts due to acidosis or hyperosmolality; drugs causing shift (beta-2 blockers, digoxin, succinylcholine, etc.); tumor lysis; crush injuries; excessive intake.
    • Inadequate excretion: ACE inhibitors/ARBs, renin inhibitors, aldosterone antagonists (spironolactone, eplerenone), ENaC inhibitors (amiloride, triamterene, trimethoprim, pentamidine), hyporeninemic hypoaldosteronism, CKD, older age, NSAIDs/COX2 inhibitors, etc.
    • Renal resistance to mineralocorticoids (SAME, Liddle’s syndrome variants, pseudohypoaldosteronism type II), or conditions causing decreased distal Na+ delivery.
    • Advanced renal failure, obstructive uropathy, tubulointerstitial diseases.
  • Clinical features: life-threatening arrhythmias, ECG changes (peaked T waves → widened QRS, sine wave, etc.), potential for paralysis or respiratory failure with severe hyperkalemia.
  • Diagnostic approach:
    • Urine analysis including osmolality, Na+, and K+ to estimate renal K+ handling; calculate transtubular potassium gradient (TTKG):
    • $TTKG = \dfrac{\dfrac{[K^+]{urine}}{[K^+]{plasma}}}{\dfrac{\text{[osm]}{urine}}{\text{[osm]}{plasma}}}$
    • Expected values: $TTKG < 3$ with hypokalemia; $TTKG > 7-8$ with hyperkalemia (though some caution exists about confounders like urea handling).
    • Check for metabolic acidosis, hydration status, and meds that affect the RAAS axis.
  • Emergency management (three stages): 1) Immediate cardiac protection: intravenous calcium (calcium gluconate 10 mL of 10% solution; or calcium chloride 3–4 mL) over 2–3 minutes; effect starts within 1–3 minutes and lasts 30–60 minutes.
    • Note: calcium should be used with caution in patients on digoxin due to potential toxicity risk.
      2) Rapid reduction of plasma K+ by redistribution into cells:
    • Insulin–glucose: 10 units insulin with 50 mL of 50% dextrose (D50W) IV; monitor for hypoglycemia; if glucose is ≥200–250 mg/dL, give insulin without glucose.
    • Beta2-agonists (albuterol): inhaled 10–20 mg (nebulized) to drive K+ into cells; expect onset ~30 minutes; monitor for tachycardia.
    • IV bicarbonate can help in metabolic acidosis but is not first-line for acute redistribution.
      3) Removal of K+ from the body:
    • Cation-exchange resins (SPS) with sorbitol; binding and fecal excretion; onset up to 24 hours; watch for intestinal necrosis risk with SPS+sorbitol.
    • Other binders: patiromer (calcium-sorbitum exchange polymer) and sodium zirconium cyclosilicate (Na+/H+ exchanger) as alternatives; these are useful for chronic management.
    • Diuretics (loop or thiazide) and/or dialysis (HD is most effective for rapid K+ removal) in appropriate settings.
  • Additional considerations:
    • Avoid rapid correction that could cause hypokalemia-related complications; monitor frequently.
    • In the setting of CKD or ESRD, dialysis may be the most reliable method for rapid K+ removal.
    • Avoid using SPS in patients with GI risk factors; prefer newer binders when feasible.
  • Practical notes on management integration:
    • If hyperkalemia coexists with metabolic acidosis, bicarbonate can help lower K+ gradually, but rapid correction should still rely on insulin/glucose and calcium protection.
    • In patients with hypertension or CKD on RAAS inhibitors, re-evaluate the necessity of these meds during hyperkalemia management.
    • Continuous ECG monitoring is essential during acute management.

Quick Reference Formulas and Thresholds (LaTeX-Formatted)

  • TBW by sex (approximate):
    • Men: TBWmen=0.60×BWTBW_{men} = 0.60 \times BW
    • Women: TBWwomen=0.50×BWTBW_{women} = 0.50 \times BW
  • Sodium deficit during hypernatremia correction (deficit to target Na+):
    • Na extsubscriptdeficit=0.6×BW×(Na<em>target−Na</em>current)\text{Na extsubscript{deficit}} = 0.6 \times BW \times (Na<em>{target} - Na</em>{current})
  • Hypernatremia water deficit (free water to replace):
    • Water deficit=(Na−140140)×TBW\text{Water deficit} = \left(\frac{Na - 140}{140}\right) \times TBW
  • Hyponatremia correction limits (risk of osmotic demyelination):
    • Acute correction target: notional rapid correction should be avoided; chronic hyponatremia correction should generally be kept to:
    • ΔNa24h+≲8−10 mM\Delta Na^{+}_{24h} \lesssim 8-10 \text{ mM}
    • ΔNa48h+≲18 mM\Delta Na^{+}_{48h} \lesssim 18 \text{ mM}
  • AVP and osmolality relationship (threshold): AVP becomes detectable around ≈285 mOsm/kg\approx 285\ \text{mOsm/kg}, with a linear AVP-osmolality relationship above threshold.
  • Renal concentrating mechanism components (abbreviated): NKCC2, AQP2, AQP3/4, ROMK, pendrin (SLC26A4), UT transporters.
  • Transtubular potassium gradient (TTKG):
    • TTKG=[K+]<em>urine/[K+]</em>plasma [osm]<em>urine/[osm]</em>plasmaTTKG = \dfrac{[K^+]<em>{urine} / [K^+]</em>{plasma}}{\,[\text{osm}]<em>{urine} / [\text{osm}]</em>{plasma}}
  • Typical expectations: TTKG<3TTKG < 3 with hypokalemia; TTKG>7−8TTKG > 7-8 with hyperkalemia (interpret with caution).
  • Hypertonic saline 3% NaCl composition (approximate): [NaCl]3%≈513 mM[NaCl]_{3\%} \approx 513\ \text{mM}; initial effect: ↑ plasma Na+ by about 1−2 mM/h1-2\ \text{mM/h} to total ~4–6 mM correction in acute hyponatremia.
  • K+ repletion rates (IV): typical ICU practice uses gradual replacement, not exceeding ~10–20 mmol/h in critical cases, and total dose limited per 100 mL saline to prevent rapid shifts.
  • Polydipsia indicator: urine osmolality <100\ \text{mOsm/kg} suggests primary polydipsia; higher osmolality suggests AVP-driven water retention.

Connections to Foundational Principles and Real-World Relevance

  • The balance of water and solute determines cell volume; deviations cause cell swelling or shrinkage with neurologic consequences (especially in hyponatremia/hypernatremia).
  • AVP is a central regulator integrating osmotic and nonosmotic stimuli to maintain circulatory integrity and osmolality; dysregulation causes most sodium disorders.
  • The kidney’s concentrating mechanism demonstrates how the body creates an osmotic gradient in the medulla to reclaim water; transporters like NKCC2, ENaC, AQP2, and urea transporters are key players.
  • Sodium disorders reflect a combination of water balance, solute handling, and neurohumoral activation (RAAS, AVP, ANP). Treatment must consider volume status, solute availability, and risks of rapid correction (ODS) or potassium shifts.
  • Clinically, SIAD is a major cause of euvolemic hyponatremia, commonly associated with small-cell lung carcinoma and certain CNS/drug etiologies; management includes fluid restriction and vaptans when indicated.
  • Hypernatremia management emphasizes gradual correction to prevent cerebral edema; DI vs primary hypodipsia requires careful diagnostic testing (DDAVP response, copeptin).
  • Potassium disorders illustrate tight coupling between Na+ reabsorption (via ENaC) and K+ secretion (ROMK/BK), and how aldosterone and renal flow influence distal secretion vs reabsorption; disturbances can reflect endocrine disease, medications, or genetic disorders (Liddle’s, SAME, Bartter, Gitelman).

Summary Takeaways

  • Osmolality and tonicity govern water movement; AVP adjusts water reabsorption to maintain 0.6–1.0 nA? (conceptual) osmolality within the narrow range.
  • Hyponatremia typologies (hypovolemic/euvolemic/hypervolemic) require careful assessment of volume status, urine Na+, and urine osmolality to identify etiology and guide therapy; avoid rapid correction to prevent ODS.
  • Hypernatremia results from water deficit (often with concomitant electrolyte loss) or Na+ gain; gradual correction is essential; DI testing (DDAVP, copeptin) helps differentiate central vs nephrogenic DI.
  • Potassium balance is governed by distal Na+ delivery, ENaC activity, and aldosterone; both hypo- and hyperkalemia have multiple etiologies and can be life-threatening; rapid, staged management is critical (calcium for cardiac safety, redistribution with insulin/glucose and beta-agonists, and removal with binders/diuretics/dialysis).